FR2896159B1 - Combinaison de derives de triazine et d'agents sensibilisateurs a l'insuline. - Google Patents

Combinaison de derives de triazine et d'agents sensibilisateurs a l'insuline.

Info

Publication number
FR2896159B1
FR2896159B1 FR0600344A FR0600344A FR2896159B1 FR 2896159 B1 FR2896159 B1 FR 2896159B1 FR 0600344 A FR0600344 A FR 0600344A FR 0600344 A FR0600344 A FR 0600344A FR 2896159 B1 FR2896159 B1 FR 2896159B1
Authority
FR
France
Prior art keywords
combination
triazine derivatives
sensitizing agents
insulin sensitizing
insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0600344A
Other languages
English (en)
French (fr)
Other versions
FR2896159A1 (fr
Inventor
Gerard Moinet
Daniel Cravo
Didier Mesangeau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sante SAS
Original Assignee
Merck Sante SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0600344A priority Critical patent/FR2896159B1/fr
Application filed by Merck Sante SAS filed Critical Merck Sante SAS
Priority to JP2008549783A priority patent/JP5249782B2/ja
Priority to PCT/EP2006/012185 priority patent/WO2007079917A2/en
Priority to CNA2006800509443A priority patent/CN101355933A/zh
Priority to CA2640897A priority patent/CA2640897C/en
Priority to ES06829706T priority patent/ES2347177T3/es
Priority to EP06829706A priority patent/EP1971330B1/en
Priority to AU2006334734A priority patent/AU2006334734B2/en
Priority to AT06829706T priority patent/ATE476179T1/de
Priority to KR1020147002582A priority patent/KR20140033498A/ko
Priority to KR20087019624A priority patent/KR101482685B1/ko
Priority to BRPI0620985A priority patent/BRPI0620985B8/pt
Priority to PL06829706T priority patent/PL1971330T3/pl
Priority to DK06829706.8T priority patent/DK1971330T3/da
Priority to EA200801676A priority patent/EA015576B1/ru
Priority to US12/160,664 priority patent/US8791115B2/en
Priority to DE602006016014T priority patent/DE602006016014D1/de
Priority to PT06829706T priority patent/PT1971330E/pt
Priority to SI200630793T priority patent/SI1971330T1/sl
Priority to ARP070100138A priority patent/AR059032A1/es
Publication of FR2896159A1 publication Critical patent/FR2896159A1/fr
Priority to IL192558A priority patent/IL192558A/en
Priority to ZA200806947A priority patent/ZA200806947B/xx
Application granted granted Critical
Publication of FR2896159B1 publication Critical patent/FR2896159B1/fr
Priority to CY20101100840T priority patent/CY1110789T1/el
Priority to US14/063,530 priority patent/US20140050786A1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR0600344A 2006-01-13 2006-01-13 Combinaison de derives de triazine et d'agents sensibilisateurs a l'insuline. Expired - Fee Related FR2896159B1 (fr)

Priority Applications (24)

Application Number Priority Date Filing Date Title
FR0600344A FR2896159B1 (fr) 2006-01-13 2006-01-13 Combinaison de derives de triazine et d'agents sensibilisateurs a l'insuline.
DK06829706.8T DK1971330T3 (da) 2006-01-13 2006-12-18 Kombination af triazinderivater og insulin-sensibilisatorer
CNA2006800509443A CN101355933A (zh) 2006-01-13 2006-12-18 三嗪衍生物与胰岛素增敏剂的组合
CA2640897A CA2640897C (en) 2006-01-13 2006-12-18 Combination of triazine derivatives and insulin sensitisers
US12/160,664 US8791115B2 (en) 2006-01-13 2006-12-18 Combination of triazine derivatives and insulin sensitisers
EP06829706A EP1971330B1 (en) 2006-01-13 2006-12-18 Combination of triazine derivatives and insulin sensitisers
AU2006334734A AU2006334734B2 (en) 2006-01-13 2006-12-18 Combination of triazine derivatives and insulin sensitisers
AT06829706T ATE476179T1 (de) 2006-01-13 2006-12-18 Kombination aus triazinderivaten und insulin- sensibilisatoren
KR1020147002582A KR20140033498A (ko) 2006-01-13 2006-12-18 트리아진 유도체 및 인슐린 감작제의 조합물
PCT/EP2006/012185 WO2007079917A2 (en) 2006-01-13 2006-12-18 Combination of triazine derivatives and insulin sensitisers
BRPI0620985A BRPI0620985B8 (pt) 2006-01-13 2006-12-18 composição farmacêutica, e usos de derivados de triazina e sensibilizadores de insulina
PL06829706T PL1971330T3 (pl) 2006-01-13 2006-12-18 Połączenie pochodnych triazyny ze środkami zwiększającymi wrażliwość na insulinę
JP2008549783A JP5249782B2 (ja) 2006-01-13 2006-12-18 トリアジン誘導体およびインスリン増感剤の組合せ
EA200801676A EA015576B1 (ru) 2006-01-13 2006-12-18 Комбинация производных триазина и сенсибилизаторов инсулина
ES06829706T ES2347177T3 (es) 2006-01-13 2006-12-18 Combinacion de derivados de triazina y sensibilizadores de insulina.
DE602006016014T DE602006016014D1 (de) 2006-01-13 2006-12-18 Kombination aus triazinderivaten und insulin-sensibilisatoren
PT06829706T PT1971330E (pt) 2006-01-13 2006-12-18 Associação de derivados de triazina e sensibilizadores de insulina
SI200630793T SI1971330T1 (sl) 2006-01-13 2006-12-18 Kombinacija derivatov triazina in insulinskih senzibilizatorjev
KR20087019624A KR101482685B1 (ko) 2006-01-13 2006-12-18 트리아진 유도체 및 인슐린 감작제의 조합물
ARP070100138A AR059032A1 (es) 2006-01-13 2007-01-12 Combinacion de derivados de triazina y sensibilizadores de insulina
IL192558A IL192558A (en) 2006-01-13 2008-07-01 A medicinal product and kit containing a combination of triazine derivatives and insulin sensitizers and its uses
ZA200806947A ZA200806947B (en) 2006-01-13 2008-08-12 Combination of triazine derivatives and insulin sensitisers
CY20101100840T CY1110789T1 (el) 2006-01-13 2010-09-16 Συνδυασμος παραγωγων τριαζινης και ευαισθητοποιητων ινσουλινης
US14/063,530 US20140050786A1 (en) 2006-01-13 2013-10-25 Combination of triazine derivatives and insulin sensitisers

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0600344A FR2896159B1 (fr) 2006-01-13 2006-01-13 Combinaison de derives de triazine et d'agents sensibilisateurs a l'insuline.

Publications (2)

Publication Number Publication Date
FR2896159A1 FR2896159A1 (fr) 2007-07-20
FR2896159B1 true FR2896159B1 (fr) 2008-09-12

Family

ID=36654309

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0600344A Expired - Fee Related FR2896159B1 (fr) 2006-01-13 2006-01-13 Combinaison de derives de triazine et d'agents sensibilisateurs a l'insuline.

Country Status (22)

Country Link
US (2) US8791115B2 (enExample)
EP (1) EP1971330B1 (enExample)
JP (1) JP5249782B2 (enExample)
KR (2) KR20140033498A (enExample)
CN (1) CN101355933A (enExample)
AR (1) AR059032A1 (enExample)
AT (1) ATE476179T1 (enExample)
AU (1) AU2006334734B2 (enExample)
BR (1) BRPI0620985B8 (enExample)
CA (1) CA2640897C (enExample)
CY (1) CY1110789T1 (enExample)
DE (1) DE602006016014D1 (enExample)
DK (1) DK1971330T3 (enExample)
EA (1) EA015576B1 (enExample)
ES (1) ES2347177T3 (enExample)
FR (1) FR2896159B1 (enExample)
IL (1) IL192558A (enExample)
PL (1) PL1971330T3 (enExample)
PT (1) PT1971330E (enExample)
SI (1) SI1971330T1 (enExample)
WO (1) WO2007079917A2 (enExample)
ZA (1) ZA200806947B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2896159B1 (fr) * 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents sensibilisateurs a l'insuline.
JP5667985B2 (ja) * 2008-12-12 2015-02-12 ポクセル インスリンとトリアジンの組合せ及び糖尿病を治療するためのその使用
CA2745854A1 (en) * 2008-12-12 2010-06-17 Daniel Cravo Tetrahydrotriazine compounds for treating diseases associated with ampk activity
FR2948027A1 (fr) * 2009-07-17 2011-01-21 Merck Sante Sas Derives amines de dihydro-1,3,5-triazine pour leur utilisation dans le traitement des maladies associees a une ischemie et/ou une reperfusion
FR2948026B1 (fr) * 2009-07-17 2011-12-02 Merck Sante Sas Derives amines de dihydro-1,3,5-triazine
TWI436768B (zh) * 2010-06-09 2014-05-11 Poxel 第２型糖尿病之治療
KR20120011667A (ko) 2010-07-29 2012-02-08 광주과학기술원 당뇨병 치료제의 스크리닝 방법
KR101271218B1 (ko) * 2012-12-07 2013-06-07 광주과학기술원 당뇨병 치료제의 스크리닝 방법
JP2020536121A (ja) 2017-10-02 2020-12-10 ポクセルＰｏｘｅｌ 駆出率が保持された心不全を治療する方法
CA3102412A1 (en) 2018-06-06 2019-12-12 Metavant Sciences Gmbh Methods of treating subjects having diabetes with chronic kidney disease
WO2019238647A1 (en) 2018-06-14 2019-12-19 Poxel Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6288095B1 (en) * 1987-09-04 2001-09-11 Beecham Group P.L.C. Compounds
US5885980A (en) * 1996-06-25 1999-03-23 Enrique G. Gutierrez Composition and method for treating diabetes
US6011049A (en) 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
TW200514783A (en) 1999-09-22 2005-05-01 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
AR030920A1 (es) 1999-11-16 2003-09-03 Smithkline Beecham Plc Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus, y procedimientos para preparar dichas composiciones
FR2804113B1 (fr) * 2000-01-26 2004-06-18 Lipha Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique
AU2001257456B2 (en) * 2000-05-01 2006-02-09 Aeropharm Technology, Inc. A core formulation
FR2853650B1 (fr) * 2003-04-10 2006-07-07 Merck Sante Sas Procede de dedoublement d'amines utiles pour le traitement de desordres associes au syndrome d'insulino-resistance
TW200526678A (en) * 2003-08-01 2005-08-16 Janssen Pharmaceutica Nv Substituted indole-O-glucosides
FR2863484B1 (fr) * 2003-12-11 2007-04-13 Oreal Utilisation de composes capables d'agir sur la voie metabolique controlee par la dopachrome tautomerase trp-2 comme agent protecteur des melanocytes du follicule pileux et applications
EP1841414A1 (en) * 2003-12-31 2007-10-10 Alpharma, Inc. Rosiglitazone and metformin formulations
FR2896159B1 (fr) * 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents sensibilisateurs a l'insuline.

Also Published As

Publication number Publication date
WO2007079917A3 (en) 2007-08-30
EP1971330A2 (en) 2008-09-24
BRPI0620985B1 (pt) 2020-04-28
JP5249782B2 (ja) 2013-07-31
FR2896159A1 (fr) 2007-07-20
CY1110789T1 (el) 2015-06-10
US8791115B2 (en) 2014-07-29
ATE476179T1 (de) 2010-08-15
AR059032A1 (es) 2008-03-12
ES2347177T3 (es) 2010-10-26
WO2007079917A2 (en) 2007-07-19
BRPI0620985B8 (pt) 2021-05-25
DK1971330T3 (da) 2010-10-25
PL1971330T3 (pl) 2011-01-31
JP2009523142A (ja) 2009-06-18
SI1971330T1 (sl) 2010-11-30
IL192558A (en) 2013-04-30
EA015576B1 (ru) 2011-10-31
BRPI0620985A2 (pt) 2011-11-29
AU2006334734A1 (en) 2007-07-19
KR20140033498A (ko) 2014-03-18
KR101482685B1 (ko) 2015-01-14
PT1971330E (pt) 2010-09-09
EP1971330B1 (en) 2010-08-04
CN101355933A (zh) 2009-01-28
CA2640897A1 (en) 2007-07-19
CA2640897C (en) 2015-10-20
EA200801676A1 (ru) 2008-12-30
US20140050786A1 (en) 2014-02-20
AU2006334734B2 (en) 2012-07-19
US20100285117A1 (en) 2010-11-11
ZA200806947B (en) 2009-11-25
KR20080088630A (ko) 2008-10-02
DE602006016014D1 (de) 2010-09-16

Similar Documents

Publication Publication Date Title
EP1973405A4 (en) HYDROXYALKYLARYLAMID DERIVATIVES
EP2011839A4 (en) INK COMBINATION
BRPI0719626A2 (pt) '' composto ''
EP1976511A4 (en) FLUORATED ARYLAMIDE DERIVATIVES
ATE552254T1 (de) Trisubstituierte aminverbindung
EP2013701A4 (en) DISAMBING OF NAMED CHARACTERS
EP2103619A4 (en) IMIDAZOTHIAZOLDERIVATE
DK1919907T5 (da) Heterocyklisk forbindelse
BRPI0716364A2 (pt) "conexço tubular"
ATE481383T1 (de) 3-aza-bicycloä3.1.0ühexanderivate
DK2351747T3 (da) Fungicide N-cycloalkylbenzylamidderivater
EP1849305A4 (en) HIDE DISORDER
EP1993492A4 (en) ORTHOSE BELOW THE BITCH
ATE413389T1 (de) Chinazolinderivate
FR2896159B1 (fr) Combinaison de derives de triazine et d'agents sensibilisateurs a l'insuline.
EP1937650A4 (en) HETEROCYCLIC COMPOUNDS
EP2062892A4 (en) MEDIUM AGAINST HYPERTONIA
EP2066640A4 (en) 2- (1-OXO-1H-ISOCHINOLIN-2-YL) ACETAMIDE DERIVATIVES
FR2896157B1 (fr) Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.
EP2042506A4 (en) SUBSTITUTED PHENYLETHINYL GOLD NITROGENATED HETEROCYCLIC CARBON COMPLEX
ATE417844T1 (de) Anthranilamid-derivate als insektizide
FR2896158B1 (fr) Combinaison de derives de triazine et d'inhibiteurs de la hmg-coa reductase.
EP1898940A4 (en) Alpha2beta1 / GPIa IIA INTEGRIN INHIBITORS
EP1990733A4 (en) ERROR DETECTOR
ITMI20042476A1 (it) Derivati indolici ad attivita' antitumorale

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20140930